Gemcitabine and R115777 (Tipifarnib) Combination Therapy for Metastatic Breast Cancer.

Trial Profile

Gemcitabine and R115777 (Tipifarnib) Combination Therapy for Metastatic Breast Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Jan 2018

At a glance

  • Drugs Gemcitabine (Primary) ; Tipifarnib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2018 Primary endpoint (Objective response rate (ORR)) has not been met, as per results published in the Investigational New Drugs.
    • 27 Jan 2018 Results assessing efficacy of combination of tipifarnib and gemcitabine published in the Investigational New Drugs.
    • 01 Jul 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top